NL-OMON22313
Not yet recruiting
Not Applicable
Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib: A Randomized Pharmacokinetic Feasibility Study.
eiden University Medical Center0 sites13 target enrollmentTBD
ConditionsCancer,Solid tumorPhase I
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cancer,Solid tumorPhase I
- Sponsor
- eiden University Medical Center
- Enrollment
- 13
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Eligible patients for study entry include patients who have histologically or cytologically confirmed diagnoses of mRCC for which pazopanib is registered as the first line treatment OR Patients with a cytological/histological diagnosis of an advanced solid tumor for whom pazopanib may be a valuable treatment option as judged by the treating physician;
- •2\. Patients must provide written informed consent prior to performance of study\-specific procedures or assessments, and must be willing to comply with treatment and follow up. Procedures conducted as part of the subject’s routine clinical management (e.g., blood count, imaging study) and obtained prior to signing of informed consent may be utilized for screening or baseline purposes provided these procedures are conducted as specified in the protocol;
Exclusion Criteria
- •1\. Current treatment in another therapeutic clinical trial;
- •2\. History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously\-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti\-seizure medication for 6 months prior to first dose of study drug;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Therapeutic Drug Monitoring to Individualize the Dosing of pazopanib: a Randomized Pharmacokinetic Feasibility Studyadvanced tumors for which no treatment options are availablerenal cell cancer10038588NL-OMON37356eids Universitair Medisch Centrum13
Not yet recruiting
Not Applicable
Therapeutic drug monitoring: Toward tailored dosing of adalimumab in rheumatoid arthritis.rheumatoid arthritisadalimumabtherapeutic drug monitoringNL-OMON29559ReumafondsReade, centrum voor revalidatie en reumatologie102
Completed
Not Applicable
therapeutic drug monitoring: towards tailored dosing of adalimumab in rheumatoid arthritisrheumatoide arthritis10003816NL-OMON41716Reade, centrum voor Revalidatie en Reumatologie55
Active, not recruiting
Phase 1
Measurement of the blood concentration of the antibiotic piperacillin and individual drug dosage in patients with febrile neutropenia after chemotherapyPatients with febrile neutropenia after myelo-suppressive chemotherapy treated with piperacillin/tazobactamTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2016-002388-33-DEFriedrich-Schiller-University Jena208
Recruiting
Phase 3
Assessment of Memantine Drug Levels in Blood Among Indian Patients with Brain Metastases Treated with Radiation TherapyHealth Condition 1: C719- Malignant neoplasm of brain, unspecifiedCTRI/2024/04/066217Amrita School of Pharmacy